Abstract
Endothelial dysfunction due to reduced bioavailability of nitric oxide (NO) is an early step in the course of atherosclerotic cardiovascular disease. NO is synthesized from L-arginine via the action of NO synthase, which is known to be blocked by endogenous L-arginine analogues such as asymmetric dimethylarginine (ADMA). ADMA is a naturally occurring amino acid found in plasma and various types of tissues. Plasma level of ADMA is reported to be associated with cardiovascular risk factors such as chronic kidney disease (CKD), being a strong predictor for cardiovascular disease and the progression of renal dysfunction in these patients. In this review, we discuss the molecular mechanisms for the elevation of ADMA levels in CKD. We also review here the pathological role for ADMA in cardiovascular complications in patients with CKD.
Keywords: ADMA, CKD, cardiovascular risk, dimethylarginine, dimethylarginine dimethylaminohydrolase, oxidative stress, NO
Current Enzyme Inhibition
Title: Role of Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease
Volume: 3 Issue: 4
Author(s): Seiji Ueda, Sho-ichi Yamagishi, Yuriko Matsumoto and Seiya Okuda
Affiliation:
Keywords: ADMA, CKD, cardiovascular risk, dimethylarginine, dimethylarginine dimethylaminohydrolase, oxidative stress, NO
Abstract: Endothelial dysfunction due to reduced bioavailability of nitric oxide (NO) is an early step in the course of atherosclerotic cardiovascular disease. NO is synthesized from L-arginine via the action of NO synthase, which is known to be blocked by endogenous L-arginine analogues such as asymmetric dimethylarginine (ADMA). ADMA is a naturally occurring amino acid found in plasma and various types of tissues. Plasma level of ADMA is reported to be associated with cardiovascular risk factors such as chronic kidney disease (CKD), being a strong predictor for cardiovascular disease and the progression of renal dysfunction in these patients. In this review, we discuss the molecular mechanisms for the elevation of ADMA levels in CKD. We also review here the pathological role for ADMA in cardiovascular complications in patients with CKD.
Export Options
About this article
Cite this article as:
Ueda Seiji, Yamagishi Sho-ichi, Matsumoto Yuriko and Okuda Seiya, Role of Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease, Current Enzyme Inhibition 2007; 3 (4) . https://dx.doi.org/10.2174/157340807782330200
DOI https://dx.doi.org/10.2174/157340807782330200 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Platelets and HIV-1 Infection: Old and New Aspects
Current HIV Research Lipid Disorders in Diabetes Mellitus and Current Management
Current Pharmaceutical Analysis Sitosterolemia: Diagnosis, Metabolic and Hematological Abnormalities, Cardiovascular Disease and Management
Current Medicinal Chemistry Cocaine and Acute Vascular Diseases
Current Drug Abuse Reviews Atherogenesis in White Coat Hypertension
Current Hypertension Reviews Neuroglobin and Estrogen Receptors: A New Pathway of Cell Survival and Cell Death Balance
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) An Association of Virus Infection with Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Patent Selections:
Recent Patents on Cardiovascular Drug Discovery From Dual Peroxisome Proliferator Activated Receptor Agonists to Selective Peroxisome Proliferator Activated Receptor Modulators
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cellular Cardiomyoplasty and Cardiac Regeneration
Current Cardiology Reviews Dietary Interventions for Atopic Disorders
Current Pharmaceutical Design Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety Role of Endothelial Nitric Oxide in Cerebrovascular Regulation
Current Pharmaceutical Biotechnology The Antiprogestogen Mifepristone: A Review
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Hypersensitivity Reactions to Anticoagulant Drugs
Current Pharmaceutical Design Targeting Inhibition of COX-2: A Review of Patents, 2002 - 2006
Recent Patents on Inflammation & Allergy Drug Discovery Pulmonary Hypertension in COPD: Pathophysiology and Therapeutic Targets
Current Drug Targets Self-Emulsifying Drug Delivery Systems: Strategy for Improving Oral Delivery of Poorly Soluble Drugs
Current Drug Therapy Targeting ADAM12 in Human Disease: Head, Body or Tail?
Current Pharmaceutical Design Should Percutaneous Coronary Intervention be the Standard Treatment Strategy for Significant Coronary Artery Disease in all Octogenarians?
Current Cardiology Reviews